Comparison of liver exposure in CT-guided high-dose rate (HDR) interstitial brachytherapy versus SBRT in hepatocellular carcinoma.
Aged
Brachytherapy
/ mortality
Carcinoma, Hepatocellular
/ mortality
Female
Humans
Image Processing, Computer-Assisted
/ methods
Liver
/ diagnostic imaging
Liver Neoplasms
/ mortality
Male
Organs at Risk
/ radiation effects
Prognosis
Radiosurgery
/ mortality
Radiotherapy Dosage
Radiotherapy Planning, Computer-Assisted
/ methods
Radiotherapy, Image-Guided
Radiotherapy, Intensity-Modulated
/ methods
Retrospective Studies
Survival Rate
Tomography, X-Ray Computed
/ methods
CT-guided interstitial brachytherapy
Hepatocellular carcinoma
Stereotactic body radiotherapy
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
06 May 2021
06 May 2021
Historique:
received:
10
11
2020
accepted:
26
04
2021
entrez:
7
5
2021
pubmed:
8
5
2021
medline:
30
11
2021
Statut:
epublish
Résumé
In unresectable hepatocellular carcinoma several local ablative treatments are available. Among others, radiation based treatments such as stereotactic body radiotherapy (SBRT) and high-dose rate interstitial brachytherapy (HDR BT) have shown good local control rates. We conducted a dose comparison between actually performed HDR BT versus virtually planned SBRT to evaluate the respective clinically relevant radiation exposure to uninvolved liver tissue. Moreover, dose coverage and conformity indices were assessed. Overall, 46 treatment sessions (71 lesions, 38 patients) were evaluated. HDR BT was applied in a single fraction with a dose prescription of 1 × 15 Gy. D98 was 17.9 ± 1.3 Gy, D50 was 41.8 ± 8.1 Gy. The SBRT was planned with a prescribed dose of 3 × 12.5 Gy (65%-Isodose), D98 was 50.7 ± 3.1 Gy, D2 was 57.0 ± 2.3 Gy, and D50 was 55.2 ± 2.3 Gy. Regarding liver exposure Vliver10Gy HDR BT can be advantageous in respect of sparing of normal liver tissue as compared to SBRT, while providing excellent target conformity.
Sections du résumé
BACKGROUND
BACKGROUND
In unresectable hepatocellular carcinoma several local ablative treatments are available. Among others, radiation based treatments such as stereotactic body radiotherapy (SBRT) and high-dose rate interstitial brachytherapy (HDR BT) have shown good local control rates.
METHODS
METHODS
We conducted a dose comparison between actually performed HDR BT versus virtually planned SBRT to evaluate the respective clinically relevant radiation exposure to uninvolved liver tissue. Moreover, dose coverage and conformity indices were assessed.
RESULTS
RESULTS
Overall, 46 treatment sessions (71 lesions, 38 patients) were evaluated. HDR BT was applied in a single fraction with a dose prescription of 1 × 15 Gy. D98 was 17.9 ± 1.3 Gy, D50 was 41.8 ± 8.1 Gy. The SBRT was planned with a prescribed dose of 3 × 12.5 Gy (65%-Isodose), D98 was 50.7 ± 3.1 Gy, D2 was 57.0 ± 2.3 Gy, and D50 was 55.2 ± 2.3 Gy. Regarding liver exposure Vliver10Gy
CONCLUSION
CONCLUSIONS
HDR BT can be advantageous in respect of sparing of normal liver tissue as compared to SBRT, while providing excellent target conformity.
Identifiants
pubmed: 33957941
doi: 10.1186/s13014-021-01812-7
pii: 10.1186/s13014-021-01812-7
pmc: PMC8103624
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
86Références
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv238-iv255
pubmed: 30285213
Lancet Oncol. 2020 Feb;21(2):e74-e82
pubmed: 32007208
Strahlenther Onkol. 2018 May;194(5):414-424
pubmed: 29404626
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
Int J Radiat Oncol Biol Phys. 2020 Jul 1;107(3):579-586
pubmed: 32188579
Radiat Oncol. 2011 Apr 17;6:40
pubmed: 21496320
J Clin Oncol. 2009 Apr 1;27(10):1572-8
pubmed: 19255321
Strahlenther Onkol. 2016 Sep;192(9):641-8
pubmed: 27393400
Cardiovasc Intervent Radiol. 2019 Feb;42(2):239-249
pubmed: 30488303
Brachytherapy. 2015 Jul-Aug;14(4):537-42
pubmed: 25944395
Radiat Oncol. 2019 Jun 11;14(1):103
pubmed: 31186023
Radiat Oncol. 2019 Jun 3;14(1):92
pubmed: 31167658
J Hepatol. 2019 Dec;71(6):1164-1174
pubmed: 31421157
J Clin Oncol. 2016 Feb 10;34(5):452-9
pubmed: 26628466
Radiat Oncol. 2020 Feb 14;15(1):37
pubmed: 32059731
J Contemp Brachytherapy. 2018 Oct;10(5):446-453
pubmed: 30479622
Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1496-505
pubmed: 15050329
Radiat Oncol. 2018 May 29;13(1):100
pubmed: 29843752
Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):776-84
pubmed: 15936559
Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):444-51
pubmed: 12957256
J Clin Oncol. 2001 Jan 1;19(1):164-70
pubmed: 11134209
Strahlenther Onkol. 2020 Apr;196(4):334-348
pubmed: 31732784
Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):479-85
pubmed: 20304566
Radiother Oncol. 2018 May;127(2):246-252
pubmed: 29510865
Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):172-9
pubmed: 20056348
Radiat Oncol. 2020 Mar 9;15(1):60
pubmed: 32151255
World J Gastrointest Oncol. 2019 May 15;11(5):367-376
pubmed: 31139307
Cardiovasc Intervent Radiol. 2015 Feb;38(1):213-21
pubmed: 24610229
Med Phys. 2019 Jul;46(7):2955-2968
pubmed: 31055834
Brachytherapy. 2017 Jul - Aug;16(4):884-892
pubmed: 28392144
Brachytherapy. 2019 Nov - Dec;18(6):823-828
pubmed: 31522972
Radiat Oncol. 2016 May 28;11:74
pubmed: 27236333
Radiat Oncol. 2021 Mar 16;16(1):51
pubmed: 33726751